Public market insider selling at Knight Therapeutics (GUD)

Public market insider selling at Knight Therapeutics (T:GUD)

Sime Armoyan, a 10% Holder, disposed of 300,000 Common Shares on a control or direction basis for registered holder Armco Alberta Inc. at a price of $6.130 on September 16th, 2024. This represents a $1,839,000 divestment of the company's shares and an account share holdings change of -2.4%.

Knight Therapeutics is in the Pharmaceuticals Sub Industry Group under the Healthcare Sector.

Knight Therapeutics Inc. is a specialty pharmaceutical company. The Company's principal business activity is developing, acquiring, in-licensing, out-licensing, manufacturing, marketing and distributing pharmaceutical products in Canada, Latin America and select international markets. It finances other life sciences companies and secures product distribution rights for Canada and select international markets. The Company invests in life sciences venture capital funds whereby the Company may receive preferential access to healthcare products for Canada and select international markets. It develops pharmaceutical products, including those to treat neglected tropical and rare pediatric diseases. The portfolio consists of pharmaceutical products with molecules and includes both in-licensed products such as Lenvima, Cresemba, Halaven, Trelstar, Akynzeo, Ambisome, Minjuvi, Imvexxy as well as products owned by Knight such as Exelon and Impavido.